Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from July 7, 2025

Partial Published before the outcome was known, scored automatically when the window closed on October 5, 2025 — -12.9% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$64.54 – $68.45Entry zone — fair-value band

$68.48Published — price the day we called it

$81.26Target — the price the thesis aimed for

$71.00Peak — highest point inside the window, not a realized return

$59.63Window close — end-of-window price, context only

What happened

Partial

Reached 19% of the predicted growth at its peak, without hitting the target.

At window close

-12.9%

realized, from the publication price to the last close inside the window

Peak gain

+3.7%

peak, from the publication price — not a realized return

S&P 500, same window

+8.1%

SPY over the identical days, dividend-adjusted

Window close

$59.63

last close inside the window, ended October 5, 2025

Peak price

$71.00

peak on July 25, 2025 — not a realized return

Days to target

—

The thesis — published July 7, 2025

Predicted growth

+20%

over the measurement window

Target price

$81.26

the price the thesis aimed for

Entry zone

$64.54 – $68.45

the fair-value band we waited for

Price at publication

$68.48

published July 7, 2025

Confidence

85%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Share price has pulled back, giving a chance to buy this leader. The stock is sitting near its longer-term average price, and two big events are coming within three months: expansion into India on July 7 and test results that could widen its heart-health claim. Investor mood is strong, and at 33 times expected profit the shares are 25% cheaper than rival Lilly, leaving space to climb toward $83 by quarter-end.

Primary drivers

India launch boosts potential customer base; obesity market grew 5x since 2021
Major study results this quarter may let Wegovy claim heart benefits
Price sitting on long-term average shows a healthy pullback for new buyers
Trades at 33x earnings versus Lilly's 45x, so it has room to close the gap

How it played out

NVO: target not reached by window end

Lyra published NVO at $68.48 on 2025-07-07 with 20% expected growth and a target of $81.26. The thesis pointed to the India launch, possible Wegovy heart-health results, a pullback near the longer-term average, and a valuation of 33 times expected profit versus Lilly's 45 times.

Inside the window, the stock peaked at $71 on 2025-07-25, a 3.7% gain. It stayed below the target and never reached it. By 2025-10-05, it ended at $59.63. The thesis did not play out on price.

What happened during the window

On 2025-07-29, Novo Nordisk lowered its 2025 sales growth outlook to 8-14% and operating profit growth outlook to 10-16%. On 2025-09-10, the company announced a restructuring with 9,000 job cuts, including 5,000 in Denmark.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals